1. Table 1. Controlled clinical trial selected to review
Author/year
Intervention
Main Outcome
Brownley et al., 2013
Receive placebo or 600 and 1000µg/day of CrPic for 6 months
↓fasting plasma glucose
↓binge eating
↓weight
HbA1c normalized in 86% of patients under CrPic treatment
Masharin et al., 2012
Received 500μg 2x/ day for 16 weeks
↑ serum chromium levels and urinary
↔ insulin sensitivity, body composition, muscle biopsies, PCR analyses, BMI, truncal fat or lipid levels
Ali et al.,2011
Offered 2 dosages (500 or 1000 µg/day) for 6 months
↔ glucose and insulin levels, insulin resistance
Krikorian et al., 2010
Received 1000 µg/day of CrPic for 12 weeks
↑ cognitive control and cerebral function
↔ depressive symptoms
↑ brain activation
Cefalu et al., 2010
Offered 1000µg/day CrPic for 24 weeks
↔body fat and composition measures of “responders” and “nonresponders”
↓myocellular and intrahepatic lipid in “responders” and “nonresponders”
Iqbal et al., 2009
Offered 1000µg/day CrPic for 16 weeks
↑acute insulin response to glucose
↔ glucose metabolism, body weight, serum lipids, inflammation and oxidative stress
Wang et al., 2007
Received 1000 µg/day of CrPic for 6 months
↑ response to chromium treatment in insulin resistant patients
Vrotvec et al., 2005
Received 1000µg CrPic for 3 months
↓ QTc interval of diabetic patients
BED: binge eating disorder; BMI: body mass index; CrPic: chromium picolinate; DM: diabetes mellitus; HbA1C: glycated hemoglobin; PCR: protein C reactive.
Bruna Marmett et al. Effects of Chromium Picolinate Supplementation on Control of Metabolic Variables: A Systematic
Review. Journal of Food and Nutrition Research, 2016, Vol. 4, No. 10, doi: /jfnr
© The Author(s) Published by Science and Education Publishing.